Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Magrolimab versus placebo with venetoclax and azacitidine in newly diagnosed AML ineligible for intensive chemotherapy
2021-003434-36Phase 3Terminated
- Sponsor
- Gilead Sciences
- Start
- Dec 2021
- Modality
- Vaccines & Immunotherapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acute myeloid leukemia (AML) comparing Magrolimab + venetoclax + azacitidine with Placebo + venetoclax + azacitidine (2 arms). Primary endpoint: Complete remission rate within 6 cycles. Started Dec 2021; status: terminated.
02
Drugs
magrolimab
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2021-003434-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003434-36.